NCT04195945View on ClinicalTrials.gov

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

June 6, 2025

Study Completion Date

December 31, 2027

Conditions
Acute Myeloid LeukemiaMyeloid Neoplasm
Interventions
DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given IV

BIOLOGICAL

Recombinant Granulocyte Colony-Stimulating Factor

Given SC

DRUG

Mitoxantrone

Given IV

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Jazz Pharmaceuticals
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER